UNSPSC 51111832: Aminoglutethimide

This classification denotes a non-steroidal aromatase inhibitor and anti-adrenal with the molecular formula C13H16N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O54ZQ14I9, chemically known as 2,6-piperidinedione, 3-(4-aminophenyl)-3-ethyl- but generally known as aminoglutethimide, which bears US NIH Compound Identifier 2145. Aminoglutethimide most often comes in base, phosphate, and racemic forms.

UNSPSC 51111832 Aminoglutethimide is a Commodity code covering active pharmaceutical ingredients and finished drugs supplied through state and local procurement channels. State and local governments acquire these products primarily through cooperative purchasing vehicles and multistate alliances that consolidate demand across participating agencies, schools, hospitals, and other public health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body for recent activity under this code, leveraging cooperative purchasing agreements to establish master contracts with pharmaceutical manufacturers and generic drug suppliers that serve multiple states and jurisdictions simultaneously.

MMCAP's Request for Proposal S1070000015802, posted January 20, 2026 with a response deadline of March 26, 2026, seeks manufacturers of generic multi-source pharmaceuticals and over-the-counter products to supply participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. Vendors must maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain minimum insurance coverage including $5 million commercial general liability and $2 million network security and privacy liability, and accept pricing evaluation weighted 75 percent on price competitiveness with remaining factors addressing administrative compliance, EDI capability, and fixed-pricing terms. Contract awards are scheduled to take effect July 1, 2026, with a two-year initial term and optional extensions at MMCAP's discretion. The RFP does not identify specific set-aside designations or budget ranges.